CHINESE JOURNAL OF DRUG EVALUATION >

2026 , Vol. 43 >Issue 1: 56 - 56-61

DOI: https://doi.org/magtech-2025-10-15-00001

Effects of Anlotinib Combined with TP Chemotherapy Regimen on Inflammatory Response and Tumor Markers in Patients with Advanced Non-Small Cell Lung Cancer

Expand
  • Department of Oncology， Henan Provincial Hospital of Traditional Chinese Medicine， Henan Zhengzhou 450002， China

Received date: 2025-10-15

  Revised date: 2025-10-29

  Accepted date: 2026-04-01

  Online published: 2026-04-01

Fold

Abstract

Objective： To evaluate the efficacy of anlotinib in combination with standard paclitaxel plus cisplatin (TP) chemotherapy in patients with advanced progressive non-small cell lung cancer (NSCLC)， and to explore its effects on serum inflammatory cytokines and tumor markers. Methods： A retrospective analysis was conducted on 94 patients with advanced progressive NSCLC who were diagnosed and received systematic treatment in our hospital from April 2020 to April 2025. Among them， 47 patients received standard TP chemotherapy (control group)， while the other 47 patients received TP chemotherapy combined with oral anlotinib (observation group). Tumor response and safety were compared between the two groups， and the patients were followed up for 12 months to assess survival outcomes， including progression-free survival (PFS) and overall survival (OS). Survival curves were plotted using the Kaplan-Meier method， and PFS and OS of the two groups were compared through the Log-rank test. Serum levels of tumor markers [carcinoembryonic antigen (CEA)， carbohydrate antigen 125 (CA125)， cytokeratin 19 fragment (Cyfra21-1)] and inflammatory factors [interleukin-2 (IL-2)， IL-10， interferon-γ (IFN-γ)] were measured before treatment and after four cycles of therapy. Results： After treatment， the disease control rate (DCR) in the observation group was significantly higher than that in the control group (P<0.05). Regarding safety， the overall incidence of proteinuria and hypertension in the observation group during treatment was higher than that in the control group (P<0.05). Follow-up results showed that the control group had a PFS of 6.95±1.71 months with 28 deaths and an OS of 7.42±1.67 months； the observation group had a PFS of 8.26±2.34 months with 17 deaths and an OS of 10.63±1.92 months. Differences between the two groups were statistically significant (χ2=7.986， 8.012， P<0.05). After treatment， levels of CEA， CA125， Cyfra21-1， and IL-10 decreased in both groups， whereas IL-2 and IFN-γ increased compared with pre-treatment levels， with more pronounced changes observed in the observation group (P<0.05). Conclusion： The addition of anlotinib to TP chemotherapy significantly improves disease control， extends PFS and OS， and modulates tumor marker levels and inflammatory responses in advanced progressive NSCLC， suggesting a potential immunomodulatory role in the tumor microenvironment. However， anlotinib is associated with increased risks of proteinuria and hypertension， warranting careful monitoring and individualized management.

Key words： ; font-size:medium; ">Non-small cell lung cancer； Advanced progression； Paclitaxel-cisplatin； Anlotinib； Survival benefit； Inflammatory cytokines； Tumor markers

Cite this article

HU Bin, DONG Liang . Effects of Anlotinib Combined with TP Chemotherapy Regimen on Inflammatory Response and Tumor Markers in Patients with Advanced Non-Small Cell Lung Cancer[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026 , 43(1) : 56 -56-61 . DOI: magtech-2025-10-15-00001

References

 [1] 何璐，李志文，孟凡青，等. 非小细胞肺癌组织病理特征与临床预后、基因组突变谱的关联研究[J]. 临床与实验病理学杂志，2025，41(1)：99-104.
     [2] 陈娟，梁龙，姚文秀. 晚期NSCLC患者外周血炎性标记物与EGFR-TKIs靶向治疗相关预后的关联及研究进展[J]. 肿瘤预防与治疗，2022，35(12)：1117-1125.
     [3] 于凯伊，戴朝霞. 一代EGFR-TKI治疗后缓慢进展的晚期NSCLC患者原药维持联合阿帕替尼的疗效及安全性[J]. 现代肿瘤医学，2019，27(22)：4001-4005.
     [4] 刘祺，周政涛，冯正富，等. 适形调强放射治疗同步TP化疗对局部晚期非小细胞肺癌患者免疫功能、全身炎症反应指标和血清肿瘤标志物的影响[J]. 现代生物医学进展，2021，21(17)：3350-3354.
     [5] 马志敏，巨晓，降文豪，等. 补肺活血胶囊联合TP方案对晚期非小细胞肺癌临床疗效、T细胞亚群及相关细胞因子的影响[J]. 河北医药，2022，44(9)：1350-1353.
     [6] 曹健，成怡楠，梁小红，等. 复肺方辅助TP方案治疗中晚期非小细胞肺癌患者的临床疗效及对其血清肿瘤标志物、生活质量的影响[J]. 世界中西医结合杂志，2023，18(1)：173-178.
     [7] 童刚，华杨，彭薇，等. TACE联合安罗替尼及信迪利单抗治疗CNLCⅡb~Ⅲb期肝癌患者的疗效及安全性评估[J]. 中国癌症杂志，2025，35(5)：478-484.
     [8] 甘钦，刘天龙，李国强. 纳武利尤单抗单药及联合安罗替尼治疗老年晚期胃癌患者的效果[J]. 中华老年多器官疾病杂志，2025，24(6)：456-460.
     [9] 吴健，李培培，祝永福，等. 基于真实世界数据的安罗替尼三线治疗晚期非小细胞肺癌的临床评价[J]. 中国药房，2025，36(12)：1488-1494.
     [10] 张旻，费霞，周新. 第8版国际肺癌TNM分期标准修订稿解读[J]. 世界临床药物，2016，37(7)：441-445.
     [11] 张淑琴，唐华，王珊珊，等. 国标ICF-RS评估肿瘤患者功能状态的信效度研究[J]. 中国康复，2025，40(3)：150-155.
     [12] 冯奉仪. 实体瘤新的疗效评价标准(解读1.1版RECIST标准)[C]. 第三届中国肿瘤内科大会论文集，2009：123-125.
     [13] 魏启明，钟胜，张海明，等. 仑伐替尼联合免疫检查点抑制剂二线治疗HAIC后进展性晚期肝细胞癌安全性和有效性[J]. 介入放射学杂志，2025，34(3)：261-267.
     [14] Han B， Li K， Wang Q， et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer： the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol，2018，4(11)：1569-1575.
     [15] 葛覃，沈健，赵荣. 安罗替尼联合PD-1抑制剂治疗晚期卵巢癌临床转归的影响因素及其预测效能[J]. 青岛大学学报（医学版），2025，61(3)：406-410.
     [16] 杨玉梅，刘雪柔，刘伟，等. 阿美替尼联合安罗替尼通过下调PI3K/AKT通路抑制非小细胞肺癌细胞的增殖[J]. 南方医科大学学报，2024，44(10)：1965-1975.
     [17] 张全，曹志坤，丁成智，等. 安罗替尼通过核因子信号通路抑制非小细胞肺癌细胞增殖、迁移和侵袭并促进细胞凋亡[J]. 中华实验外科杂志，2024，41(12)：2778-2782.
     [18] 苏雨栋，赵强. 安罗替尼对MYCN扩增神经母细胞瘤增殖凋亡与迁移侵袭的影响及机制研究[J]. 中国肿瘤临床，2024，51(24)：1250-1254.
     [19] 何广，冀东，宋翠萍，等. 肿瘤相关巨噬细胞内SHP-2过表达通过激活PI3K/mTOR通路加速血管新生促进乳腺癌进展的研究[J]. 中国肿瘤外科杂志，2025，17(3)：291-298.
     [20] 曹赛雅，陈超，王杰. 肿瘤血管新生在肿瘤免疫治疗中的研究进展[J]. 肿瘤，2023，43(7)：626-634.
     [21] 徐可佩，方晓政，林怡，等. MRI影像组学与乳腺癌肿瘤新生血管相关性研究[J]. 磁共振成像，2022，13(8)：146-149.
     [22] 洪乔军，韩冬冬，方瑜，等. 免疫检查点抑制剂联合安罗替尼治疗晚期非小细胞肺癌的临床疗效[J]. 临床药物治疗杂志，2024，22(8)：63-68.
     [23] 晏芾，滕悦，俞心念，等. 安罗替尼联合PD-1抑制剂二线治疗老年晚期肺腺癌患者的疗效及对T淋巴细胞亚群的影响[J]. 南京医科大学学报（自然科学版），2023，43(4)：550-554.
     [24] 杨玉翠，徐玉良，肖李帅，等. 安罗替尼联合卡瑞利珠单抗对广泛期小细胞肺癌维持治疗的疗效与安全性观察[J]. 临床肺科杂志，2024，29(8)：1200-1205.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]